CenterBook Partners LP Makes New Investment in Viridian Therapeutics, Inc. $VRDN

CenterBook Partners LP purchased a new position in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 136,717 shares of the company’s stock, valued at approximately $4,255,000. CenterBook Partners LP owned 0.14% of Viridian Therapeutics as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. ANTIPODES PARTNERS Ltd purchased a new position in shares of Viridian Therapeutics during the 4th quarter worth $36,000. Aster Capital Management DIFC Ltd acquired a new stake in shares of Viridian Therapeutics during the 3rd quarter worth $35,000. Bessemer Group Inc. increased its holdings in shares of Viridian Therapeutics by 947.7% during the 3rd quarter. Bessemer Group Inc. now owns 2,085 shares of the company’s stock worth $45,000 after buying an additional 1,886 shares during the last quarter. Larson Financial Group LLC acquired a new stake in shares of Viridian Therapeutics during the 3rd quarter worth $52,000. Finally, US Bancorp DE increased its holdings in shares of Viridian Therapeutics by 23.2% during the 3rd quarter. US Bancorp DE now owns 2,457 shares of the company’s stock worth $53,000 after buying an additional 463 shares during the last quarter.

Viridian Therapeutics Trading Down 0.3%

NASDAQ:VRDN opened at $15.73 on Tuesday. The business’s 50-day moving average is $16.36 and its two-hundred day moving average is $25.64. The company has a debt-to-equity ratio of 0.10, a current ratio of 15.15 and a quick ratio of 15.15. Viridian Therapeutics, Inc. has a 12 month low of $13.18 and a 12 month high of $34.29. The firm has a market capitalization of $1.62 billion, a PE ratio of -4.74 and a beta of 0.90.

Viridian Therapeutics (NASDAQ:VRDN) last released its quarterly earnings data on Tuesday, May 5th. The company reported ($0.90) EPS for the quarter, beating the consensus estimate of ($1.06) by $0.16. Viridian Therapeutics had a negative return on equity of 80.19% and a negative net margin of 490.31%.The company had revenue of $0.14 million for the quarter, compared to analyst estimates of $0.04 million. During the same period last year, the company posted ($0.87) earnings per share. The firm’s revenue was up 95.8% compared to the same quarter last year. Research analysts predict that Viridian Therapeutics, Inc. will post -3.87 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

VRDN has been the subject of a number of research analyst reports. Needham & Company LLC restated a “buy” rating and set a $32.00 price objective on shares of Viridian Therapeutics in a report on Tuesday, May 5th. Truist Financial dropped their price objective on Viridian Therapeutics from $36.00 to $33.00 and set a “buy” rating for the company in a report on Tuesday, April 21st. The Goldman Sachs Group dropped their price objective on Viridian Therapeutics from $36.00 to $31.00 and set a “buy” rating for the company in a report on Tuesday, April 7th. HC Wainwright dropped their price objective on Viridian Therapeutics from $34.00 to $22.00 and set a “buy” rating for the company in a report on Tuesday, March 31st. Finally, Stifel Nicolaus set a $39.00 price objective on Viridian Therapeutics in a report on Wednesday, May 13th. Twelve research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Viridian Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $36.14.

Insider Buying and Selling at Viridian Therapeutics

In other Viridian Therapeutics news, Director Fairmount Funds Management Llc bought 1,176,470 shares of the stock in a transaction dated Monday, May 11th. The stock was bought at an average cost of $17.00 per share, for a total transaction of $19,999,990.00. Following the completion of the purchase, the director directly owned 5,090,928 shares of the company’s stock, valued at approximately $86,545,776. The trade was a 30.05% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 2.40% of the stock is owned by corporate insiders.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.